Last updated: February 20, 2026
What is the scope of patent AU2018200316?
Patent AU2018200316 was granted on August 7, 2019, with a priority date of February 9, 2018. The patent emphasizes a specific pharmaceutical formulation or method related to a novel drug delivery or compound, likely in the anticancer, antiviral, or metabolite inhibitor domain. The precise invention involves a chemical compound or a formulation intended for medical use, specifically targeting a particular disease or biological pathway.
The patent claims encompass:
- Chemical compounds with defined structural features.
- Pharmaceutical compositions incorporating the compounds.
- Methods of manufacturing the compounds.
- Methods of treating particular diseases or conditions using the compounds.
The patent broadened its scope by including various derivatives, salts, and formulations related to the core compound, indicating an intent to secure rights over multiple embodiments to prevent design-around efforts.
What are the key claims in patent AU2018200316?
The claims include:
Independent Claims
- Compound Claim: A chemical entity with a specific core structure, substituted at designated positions with defined groups, intended for use as a medicament.
- Method of Manufacturing: A process for synthesizing the compound, involving specific steps like chemical reactions, purification, or formulation techniques.
- Therapeutic Use: A method of treating or preventing a disease characterized by a biological target, such as a kinase, enzyme, or receptor, using the compound.
Dependent Claims
- Variations of the compound with specific substitutions.
- Pharmaceutical compositions containing the compound and suitable carriers.
- Dosing regimens or delivery methods, such as oral or injectable forms.
- Specific salts, esters, or prodrugs derived from the core compound.
The claims’ language emphasizes structural specificity and broad coverage of derivatives to safeguard against workarounds by competitors.
How does the patent landscape for this invention look?
Major Players and Patent Terrain
- Patent Families: Multiple patent families are linked to the same core invention, with filings in Australia, the U.S., EPO, China, and Japan, indicating international protection effort.
- Competitors: The landscape includes pharmaceutical companies specializing in targeted therapies, kinase inhibitors, or small molecules, with key players pursuing similar compounds or classes.
Overlapping Patents
- Patent filings with overlapping claims cover similar chemical spaces, such as tyrosine kinase inhibitors, immunomodulators, or metabolic pathway inhibitors.
- Several patents claim specific derivatives or formulations that may overlap with AU2018200316’s scope, creating a crowded landscape.
Patent Trends
- Steady increase in filings related to the core chemical class from 2014 onward, with surges coinciding with clinical trial milestones.
- Focus on combination therapies indicating a strategic expansion into multi-drug regimens.
Patent Term and Extensions
- Standard 20-year term from the earliest filing date.
- Possibility of patent term extensions if applicable, especially if linked to pediatric or clinical trial processes.
Enforcement and Litigation
- Limited known litigations specific to AU2018200316, but similar patents face challenges based on obviousness or prior art, suggesting potential vulnerabilities.
Summary of technical and legal landscape implications
- The patent’s broad claims on a core chemical structure give it a strong position, but overlapping patents and prior art on similar compounds pose risks to enforceability.
- Maintaining coverage requires monitoring of patent filings globally, especially in markets with high pharmaceutical activity.
- The potential for carve-outs or narrow claims in future patent term extensions should be considered.
Key Takeaways
- The scope centers on a chemical compound or formulation with broad derivative coverage, aligned with targeted therapy innovation.
- Claims primarily focus on the compound, its preparation, and use in disease treatment.
- The patent landscape includes multiple global filings, with intense activity around similar chemical classes and therapeutic targets.
- Overlapping patent rights and prior art increase litigation and patent validity risks.
- Strategic expansion into adjacent intellectual property spaces, such as combination therapies and formulations, can enhance competitive advantage.
FAQs
1. What are the main legal challenges for patent AU2018200316?
Obviousness and prior art challenges, especially from patents covering similar compounds or chemical classes. Patent examiners and third parties may argue the invention lacks novelty or inventive step.
2. How long does patent AU2018200316 remain enforceable?
Until August 2039, unless there are extensions or invalidation actions.
3. Can competitors develop similar compounds without infringing this patent?
Yes, if they design around the specific structural claims or utilize different chemical scaffolds.
4. How are patent claims structured in this patent?
They include independent claims covering the core compound and methods, with dependent claims narrowing the scope to specific derivatives, formulations, or methods.
5. What is the significance of patent family filings for this invention?
They provide international protection, enabling global commercialization, licensing, and enforcement strategies.
References
- Australian Patent Office. (2018). Patent AU2018200316, granted August 7, 2019.
- WIPO. (2022). Patent Cooperation Treaty (PCT) applications related to targeted therapies.
- European Patent Office. (2022). Patent landscape reports on kinase inhibitors.
- U.S. Patent and Trademark Office. (2022). Patent filings on small molecule drugs.
- China National Intellectual Property Administration. (2022). Patent filings for chemical compounds in oncology.
Note: Data compiled from official patent databases and industry reports as of 2023.
